Granite Point Capital Management, L.P. Sage Therapeutics, Inc. Transaction History

Granite Point Capital Management, L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 13, 2018	SELL	$138.11 - $169.04 $1.37 Million - $1.67 Million	-9,900 Closed	0 $0
Q2 2018 Aug 13, 2018	SELL	$140.36 - $175.76 $2.04 Million - $2.55 Million	-14,500 Reduced 59.43%	9,900 $1.55 Million
Q1 2018 May 15, 2018	BUY	$152.15 - $192.33 $973,760 - $1.23 Million	6,400 Added 35.56%	24,400 $3.93 Million
Q4 2017 Feb 08, 2018	BUY	$60.72 - $167.34 $1.09 Million - $3.01 Million	18,000	18,000 $2.97 Million

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $326M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Granite Point Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Granite Point Capital Management, L.P. with notifications on news.